1228585-88-3
GS9620
CAS: 1228585-88-3
Molecular Formula: C22H30N6O2
1228585-88-3 - Names and Identifiers
1228585-88-3 - Physico-chemical Properties
| Molecular Formula | C22H30N6O2 |
| Molar Mass | 410.51 |
| Density | 1.247±0.06 g/cm3(Predicted) |
| Water Solubility | Soluble in DMSO (10 mg/ml) |
| Solubility | Soluble in DMSO (10 mg/ml) |
| Appearance | Morphological solid color Off-white |
| Color | Off-white |
| pKa | 10.34±0.20(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Use | GS-9620 is an oral Toll-Like Receptor-7(TLR-7) agonist and is used as a potential treatment for HIV infection. |
| In vitro study | GS-9620 effectively inhibited Virus replication of peripheral blood mononuclear cells, especially GS-9620 treated 24 hours to 48 hours prior to HIV infection. Loss of pDCs, but not other subsets of immune cells derived from peripheral blood mononuclear cells, inhibited antiviral activity by GS-9620. |
| In vivo study | Short-term oral GS-9620 will produce long-term inhibition of HBV DNA in serum and liver. GS-9620 treatment induces the production of IFN-α and other cytokines, chemokines, and activates ISGs, natural killer cells and lymphocyte subsets. It can also reduce Virus DNA, HB surface antigen in serum levels, HB e antigen and HBV antigen positive number of liver cells, enhance hepatocyte apoptosis. Currently, GS-9620 are in clinical laboratory evaluation for the treatment of chronic HBV infection and the reduction of latent Virus pool in Virus of patients with suppressed HIV infection. |
1228585-88-3 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.436 ml | 12.18 ml | 24.36 ml |
| 5 mM | 0.487 ml | 2.436 ml | 4.872 ml |
| 10 mM | 0.244 ml | 1.218 ml | 2.436 ml |
| 5 mM | 0.049 ml | 0.244 ml | 0.487 ml |
Last Update：2024-01-02 23:10:35
1228585-88-3 - Reference Information
| biological activity | GS-9620 is an oral Toll-Like Receptor-7(TLR-7) agonist, which is used as a potential treatment for HIV infection. |
| target | TargetValue TLR7 |
| Target | Value |
| in vitro studies | GS-9620 effectively inhibit viral replication of peripheral blood mononuclear cells, especially when GS-9620 are treated 24 to 48 hours before HIV infection. Loss of pDCs, rather than other immune cell subsets derived from peripheral blood mononuclear cells, inhibits the antiviral activity of GS-9620. |
| in vivo studies | short-term oral GS-9620 will produce long-term inhibition of HBV DNA in serum and liver. GS-9620 treatment induces the production of IFN-α and other cytokines and chemokines, and activates ISGs, natural killer cells and lymphocyte subsets. It can also reduce the levels of viral DNA and HB surface antigen in serum, the number of HB e antigen and HBV antigen positive hepatocytes, and enhance hepatocyte apoptosis. At present, the GS-9620 is in clinical examination and evaluation to test its effect on the treatment of chronic HBV infection and the reduction of hidden virus reservoir in patients with virus inhibition of HIV infection. |
Last Update：2024-04-09 21:54:55
1228585-88-3 - Target
| Target | Value |
| TLR7 |
Last Update：2024-04-09 01:59:50
Supplier List
Spot supply
Product Name: GS-9620 Visit Supplier Webpage Request for quotationCAS: 1228585-88-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: GS-9620 Visit Supplier Webpage Request for quotationCAS: 1228585-88-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History